What's New in Guidelines & Advice

All documents recently added to the Guidelines & Advice area within the last 6 months are available here, as well as any updated documents.

Recommendations for the Management of Actionable Incidental Findings in the Lung Cancer Screening Pilot for People at High Risk

Document Status: Current

New

Oct 2020

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Document Status: Current

ID: GL 4-18

Version: N/A

New

Sep 2020

Risk Reduction Strategies for BRCA1/2 Hereditary Ovarian Cancer Syndromes

Document Status: Current

ID: GL #4-4v2

Version: 2

Sep 2020

Summary of Recommendations for Primary Care Management after Stem Cell Transplant

Document Status: Current

Version: 1

Jul 2020

Screening for Secondary Solid Malignancies after Stem Cell Transplant

Document Status: Current

Version: 1

Jul 2020

Cancer and the Health Effects of Cannabis and Cannabinoids: An update of the systematic review by the National Academies of Sciences, Engineering, and Medicine (2017) Consensus Study Report

Document Status: Current

ID: ES 23-2

Version: N/A

Jun 2020

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2019

Document Status: Current

ID: PET 2019-2

Version: N/A

Jun 2020

First-Line Therapy, Autologous Stem Cell Transplantation, and Post-Transplant Maintenance in the Management of Patients Newly Diagnosed with Mantle Cell Lymphoma

Document Status: Current

ID: RR SCT-9

Version: N/A

Jun 2020

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Document Status: Current

ID: GL END 3-22

Version: N/A

Apr 2020

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

Document Status: Current

ID: GL END 7-3

Version: 4

Apr 2020